Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
Enasidenib Plus Azacitidine Significantly Improves Responses in Newly Diagnosed IDH2-Mutated AML
Gilteritinib Approved in Europe for Relapsed/Refractory FLT3+ AML
Novel Agents, Combo Regimens Poised to Dominate AML Treatment
Related Videos
Dr. Perl on Challenges of Implementing Immunotherapy in AML
Dr. Schiller on the Heterogeneity of AML
Dr. Schiller on Venetoclax and Glasdegib in AML
News >

FDA Approves Gilteritinib for FLT3+ AML

Jason M. Broderick @jasoncology
Published: Wednesday, Nov 28, 2018

The FDA has approved gilteritinib (Xospata) for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).

The CR rate was 11.6% (n = 16) and the CRh rate was 9.4% (n = 13). The median time to first response was 3.6 months (range, 0.9-9.6) among patients reaching CR/CRh.


During any 56-day post-baseline period, 33 (31.1%) of the 106 patients dependent on red blood cell (RBC) and/or platelet transfusions at baseline became independent of such transfusions. Seventeen (53.1%) of the remaining 32 patients who were RBC/platelet-transfusion independent at baseline remained independent of transfusion during any 56-day post-baseline period.

... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Other News on Hematologic Oncology
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
 
x